<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04303390</url>
  </required_header>
  <id_info>
    <org_study_id>SBCC-2017-14</org_study_id>
    <nct_id>NCT04303390</nct_id>
  </id_info>
  <brief_title>24 Vs 48 Hours of Cefazolin or Cefuroxime as Prophylaxis</brief_title>
  <official_title>24 Versus 48 Hours of First Generation or Second Generation Cephalosporin as Prophylaxis to Reduce Surgical Site Infection in Adult Cardiac Surgery Patients: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saud Al Babtain Cardiac Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Saud Al Babtain Cardiac Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized control trial studying the effect of prophylactic antibiotics to reduce surgical
      site infections following cardiac surgery in adults using 1st generation cephalosporin
      (Cefazolin) or 2nd generation cephalosporin (Cefuroxime).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective randomized controlled patient blinded study with 2x2 factional design. It aims
      to study optimal duration of antibiotic to reduce surgical site infections following cardiac
      surgery in adults 24 or 48 hours using 1st generation cephalosporin (Cefazolin) or 2nd
      generation cephalosporin (Cefuroxime). Patients shall remain on either medicines for 24 or 48
      hours. The primary endpoints of the study are:(1) 48 hours antibiotic prophylaxis is superior
      to 24 hours in adult cardiac surgery (2) Cefuroxime is superior to Cafazolin as a
      prophylactic antibiotic in adult cardiac surgery. Secondary endpoints include; organisms
      causing surgical site infections, length of hospital and ICU stay, and worsening in renal
      function.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 5, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>50% of study patients will be assigned to first generation cephalosporin while the other 50% will be assigned to the second generation cephalosporin. 50% of the entire study participants will be assigned to 24 hour therapy while the other 50% will be assigned to 48 hours</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>surgical site infection rate is less with Cefuroxime than Cefazolin</measure>
    <time_frame>within 3 months from date of surgery</time_frame>
    <description>that Second Generation Cefalosporin is superior to first generation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>surgical site infection rate is less with 48 hours rather than 24 hours</measure>
    <time_frame>within 3 months from date of surgery</time_frame>
    <description>That Longer duration of prophylaxis is better than shorter duration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of actual Hospital Stay in the group assigned to 48 hours of cefuroxime</measure>
    <time_frame>within 3 months from date of surgery</time_frame>
    <description>that 48 hours of cefuroxime will reduce hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU Stay will be shorter in the group assigned to 48 hours of cefuroxime</measure>
    <time_frame>within 3 months from date of surgery</time_frame>
    <description>that 48 hours of cefuroxime will reduce ICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of infection with a specific organism following each of the antibiotics used</measure>
    <time_frame>within 3 months from date of surgery</time_frame>
    <description>type of organism following each type of antibiotic used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline of serum creatinine for each antibiotic used</measure>
    <time_frame>within 3 months from date of surgery</time_frame>
    <description>that 48 hours of cefuroxime will not worsen renal function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate associated with use of each antibiotic used</measure>
    <time_frame>within 3 months from date of surgery</time_frame>
    <description>that 48 hours of cefuroxime might reduce mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of infection other than surgical site following each of the antibiotics used</measure>
    <time_frame>within 3 months from date of surgery</time_frame>
    <description>that this will not be affected by the antibiotic used</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">520</enrollment>
  <condition>Surgical Site Infection</condition>
  <arm_group>
    <arm_group_label>24 hour Cefuroxime arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25% of the entire study participants are assigned to 24 hours and second generation cephalosporin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>24 hour Cefazolin arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25% of the entire study participants are assigned to 24 hours and first generation cephalosporin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>48 hour Cefuroxime arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25% of the entire study participants are assigned to 48 hours and second generation cephalosporin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>48 hour Cefazolin arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25% of the entire study participants are assigned to 48 hours and first generation cephalosporin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefuroxime</intervention_name>
    <description>second generation cephalosporin</description>
    <arm_group_label>24 hour Cefuroxime arm</arm_group_label>
    <arm_group_label>48 hour Cefuroxime arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefazolin Injection</intervention_name>
    <description>First generation cephalosporin</description>
    <arm_group_label>24 hour Cefazolin arm</arm_group_label>
    <arm_group_label>48 hour Cefazolin arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>24 hours</intervention_name>
    <description>Duration of antibiotic therapy</description>
    <arm_group_label>24 hour Cefazolin arm</arm_group_label>
    <arm_group_label>24 hour Cefuroxime arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>48 hours</intervention_name>
    <description>Duration of antibiotic therapy</description>
    <arm_group_label>48 hour Cefazolin arm</arm_group_label>
    <arm_group_label>48 hour Cefuroxime arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide informed consent

          -  Planned to undergo a cardiac surgical procedure

        Exclusion Criteria:

          -  Patients on antibiotics on the day of surgery or those who received any within 7 days
             for any reason

          -  Patients taken to operating room as salvage

          -  Patients who are allergic to either cefuroxime or cefazolin

          -  Patients for LVAD or ECMO

          -  Patients who are known MRSA carriers

          -  Patients receiving steroid therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammed S Koudieh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saud AlBabtain Cardiac Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shukri M AlSaif, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saud AlBabtain Cardiac Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dina F AlBiliwi, RN</last_name>
    <phone>+966138517569</phone>
    <email>dina.albiliwi@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raja J Aljumaian, RN</last_name>
    <phone>+966138517553</phone>
    <email>rajaa83.j@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Saud AlBabtain Cardiac Center</name>
      <address>
        <city>Dammam</city>
        <state>Eastern Province</state>
        <zip>31463</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 3, 2019</study_first_submitted>
  <study_first_submitted_qc>March 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2020</study_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Surgical Wound Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefazolin</mesh_term>
    <mesh_term>Cefuroxime</mesh_term>
    <mesh_term>Cefuroxime axetil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

